Role of a Modified Urothelium Immune Prognostic Index in Patients With Metastatic Urothelial Carcinoma Treated With Anti–PD-1/PD-L1–Based Therapy

Role of a Modified Urothelium Immune Prognostic Index in Patients With Metastatic Urothelial Carcinoma Treated With Anti–PD-1/PD-L1–Based Therapy

Introduction: The use of antibodies against programmed death receptor-1 (PD-1) and its ligand (PD-L1) has improved survival in metastatic urothelial carcinoma (mUC) patients. However, reliable and convenient biomarkers of early responses and outcomes are still lacking.Materials and Methods: We retro...

Full description

Bibliographic Details
Main Authors: Haifeng Li, Xin An, Riqing Huang, Lu Li, Chengbiao Chu, Wei Yang, Zike Qin, Zhuowei Liu, Fangjian Zhou, Cong Xue, Yanxia Shi
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Molecular Biosciences
Subjects:
PD-1 inhibitor
LDH
NLR
urothelial carcinoma
mUIPI
Online Access:https://www.frontiersin.org/articles/10.3389/fmolb.2021.621883/full

Internet

https://www.frontiersin.org/articles/10.3389/fmolb.2021.621883/full

Similar Items